# Safety and Efficacy of Tofacitinib in Hospitalized Participants With COVID-19 Pneumonia Who Are Receiving Standard of Care Therapy

> **NCT04412252** · PHASE2 · WITHDRAWN · sponsor: **Pfizer**

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Tofacitinib
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04412252
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-07-06
- **Primary completion:** 2020-09-16
- **Final completion:** 2020-10-18
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Due to the pursuit of other SARS-CoV-2-related research including alternative trials with tofacitinib, this trial was canceled prior to subject enrollment.
- **Last updated:** 2020-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04412252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04412252, "Safety and Efficacy of Tofacitinib in Hospitalized Participants With COVID-19 Pneumonia Who Are Receiving Standard of Care Therapy". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04412252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*